HALOZYME THERAPEUTICS, INC. - Common Stock (HALO)

Q2 2023 13F Holders as of 30 Jun 2023

Type / Class
Equity / Common Stock
Shares outstanding
123,650,000
Total 13F shares
121,230,022
Share change
-2,366,801
Total reported value
$4,374,488,165
Put/Call ratio
147%
Price per share
$36.07
Number of holders
364
Value change
-$98,141,903
Number of buys
176
Number of sells
187

Institutional Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q2 2023

As of 30 Jun 2023, HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) was held by 364 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 121,230,022 shares. The largest 10 holders included BlackRock Inc., VANGUARD GROUP INC, Artisan Partners Limited Partnership, STATE STREET CORP, SNYDER CAPITAL MANAGEMENT L P, JPMORGAN CHASE & CO, MACQUARIE GROUP LTD, GEODE CAPITAL MANAGEMENT, LLC, Invesco Ltd., and GW&K Investment Management, LLC. This page lists 368 institutional shareholders reporting positions in this security for the Q2 2023 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.